Age-dependent eradication of Helicobacter pylori in Japanese patients.
OBJECTIVE
To determine the general risk factors affecting the failure rate of first-line eradication therapy in Japanese patients with Helicobacter pylori (H. pylori) infection.


METHODS
The present study enrolled 253 patients who had an H. pylori infection, underwent gastro-endoscopy, and were treated with H. pylori eradication therapy. Eradication therapy consisted of 30 mg lansoprazole plus 750 mg amoxicillin and 400 mg clarithromycin twice daily for 7 d. All of the patients underwent a 13C urea breath test at least 1 mo after the completion of eradication therapy. The current study investigated the independent factors associated with successful H. pylori eradication using a multiple logistic regression analysis.


RESULTS
The overall success rate in the patients was 85.8%. Among the general factors examined in the multivariate analyses, only having an age less than 50 years was found to be significantly associated with a poor response to H. pylori eradication. Moreover, side effects were the only clinical factors in the patients who were under 50 years of age that significantly influenced the poor response to H. pylori eradication.


CONCLUSIONS
H. pylori-positive elderly patients should undergo eradication therapy. In addition, it is necessary to improve H. pylori eradication therapy in younger patients.
Mamori
Satoshi
S
Department of Gastroenterology and Hepatology, Shinko Hospital, 1-4-47 Wakihama-cho, Chuo-ku, Kobe, Hyogo 651-0072, Japan. m8583jp@yahoo.co.jp
Higashida
Akihiro
A
Kawara
Fumiaki
F
Ohnishi
Katsuhiro
K
Takeda
Akihiko
A
Senda
Eri
E
Ashida
Cho
C
Yamada
Hajime
H
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology*; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000208:ethnology / Q000503:physiopathology*; D016480:Helicobacter pylori; D006801:Humans; D007564:Japan; D064747:Lansoprazole; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D017211:Treatment Failure
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin
Ann Intern Med. 2007 Oct 16;147(8):553-62
17938394
Helicobacter. 2006 Dec;11(6):562-8
17083378
World J Gastroenterol. 2008 Sep 21;14(35):5385-402
18803350
World J Gastroenterol. 2005 Dec 21;11(47):7520-4
16437727
Aliment Pharmacol Ther. 1999 Aug;13(8):1047-55
10468680
Am J Gastroenterol. 1999 Jul;94(7):1751-9
10406231
Am J Gastroenterol. 2005 Aug;100(8):1696-701
16086704
Aliment Pharmacol Ther. 2002 Jul;16(7):1269-75
12144576
Am J Gastroenterol. 2000 Dec;95(12):3393-8
11151867
Helicobacter. 1997 Dec;2(4):185-7
9421121
Drugs. 1999 Jun;57(6):905-20
10400404
N Engl J Med. 2002 Oct 10;347(15):1175-86
12374879
Aliment Pharmacol Ther. 2002 Feb;16(2):167-80
11860399
Helicobacter. 2007 Nov;12 Suppl 2:50-8
17991177
Aliment Pharmacol Ther. 2000 Oct;14(10):1319-28
11012477
Am J Gastroenterol. 1998 Sep;93(9):1432-5
9732920
Am J Gastroenterol. 2005 Sep;100(9):1935-40
16128936
Aliment Pharmacol Ther. 2003 Jun 1;17(11):1381-7
12786632
Aliment Pharmacol Ther. 2004 Jul 1;20(1):99-107
15225176
Dig Dis Sci. 2000 Jan;45(1):68-76
10695616
Am J Gastroenterol. 1998 Nov;93(11):2106-12
9820381
Am J Gastroenterol. 1998 Dec;93(12):2330-8
9860388
Gut. 2004 Sep;53(9):1374-84
15306603
Gut. 2007 Jun;56(6):772-81
17170018
Aliment Pharmacol Ther. 2003 Apr;17(8):1065-74
12694089
Best Pract Res Clin Gastroenterol. 2004;18 Suppl:73-81
15588798